<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426023</url>
  </required_header>
  <id_info>
    <org_study_id>eudract 2006-003689-32</org_study_id>
    <secondary_id>FARM5YZTZW</secondary_id>
    <secondary_id>ALMA1</secondary_id>
    <nct_id>NCT00426023</nct_id>
  </id_info>
  <brief_title>Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis</brief_title>
  <official_title>Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Cyclosporine Eye Drop Treatment in Preventing Vernal Keratoconjunctivitis (VKC) Relapses and in Treating the Acute Phase.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Genova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <brief_summary>
    <textblock>
      This interventional study aims to evaluate the efficacy of Cyclosporine eye drop treatment in
      preventing relapses of Vernal Keratoconjunctivitis (VKC) and in treating the acute phases of
      the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vernal keratoconjunctivitis (VKC) is a severe allergic disease, characterised by chronic
      ocular surface inflammation with seasonal relapses. Active phases of VKC require treatment
      with topical steroids to control inflammation and corneal damage that may lead to impairment
      of visual function and severe ocular discomfort. To date, safe and effective therapies in
      preventing relapses and controlling active phases of VKC are not available. Few controlled
      trials have used topical Cyclosporine A (CsA) for the treatment of VKC. The present
      multicenter, double-masked, randomised, controlled clinical trial will allow to obtain
      further data on the safety and efficacy of topical treatment with Cyclosporine in patients
      affected by VKC. Moreover, this study will evaluate the efficacy of topical CsA in both
      preventing the relapses of VKC and controlling the active phases of the disease. It is
      important to highlight that Cyclosporine eye drops are not currently commercially available
      in Italy and must be custom-made by specialized pharmacies. As VKC mostly affects young
      patients, it influences their daily life and their social interactions. Moreover, the severe
      signs and symptoms of the disease result in frequent ophthalmologic controls, influencing
      school activities of children and working days for their parents with a relevant economic
      cost for the National Health System.

      Comparisons: Efficacy of Cyclosporine A 0.05% eye-drops in preventing VKC relapses compared
      to standard antiallergic (Ketotifen fumarate 0.025% eye-drops) treatment, and efficacy of
      Cyclosporine A 0.1% eye-drops in controlling acute phases compared to antiinflammatory
      (Desametasone 0.15% eye drops) treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the number of relapses of ocular inflammation per year between cyclosporine and ketotifen treated groups. Relapses are defined as at least 100% increase of the sum of hyperemia, itching, Trantas dots and corneal involvement</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences of specific symptoms and signs, of TSyS, TSS, Quick questionnaire subscales and biochemical and</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>molecular parameters will be evaluated at baseline, after 1, 3 and 6 months of treatment and after 1 month of treatment discontinuation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Vernal Keratoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this group of patients is treated with the experimental drug (Cyclosporine A 0,05% eye drops) 2 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A 0,05% eye drop</intervention_name>
    <description>Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>NOVA22007</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketotifen fumarate 0.025% eye drops</intervention_name>
    <description>ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zaditen collirio monodose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients affected by VKC will be enrolled by the three Centres involved in the project

          -  Diagnosis of VKC will be performed on the basis of personal and family history of
             systemic allergic diseases, clinical examination (presence of conjunctival tarsal
             and/or limbal papillae) and presence of eosinophils in the conjunctival scraping

        Exclusion Criteria:

          -  Contact lens wearers

          -  Patients affected by other ocular diseases

          -  Patients subjected to ocular surgery in the preceding 6 months

          -  Patients under eye drop or systemic treatments for other diseases, or

          -  Patients enrolled in experimental trials in the preceding 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>alessandro lambiase, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rome Campus Bio-Medico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padua</name>
      <address>
        <city>Padua</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rome Campus Bio-Medico</name>
      <address>
        <city>Rome</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O, Rama P, Magrini L, Juhas T, Bucci MG. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology. 2000 Jun;107(6):1157-63.</citation>
    <PMID>10857837</PMID>
  </reference>
  <reference>
    <citation>Bonini S, Lambiase A, Sgrulletta R, Bonini S. Allergic chronic inflammation of the ocular surface in vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2003 Oct;3(5):381-7. Review.</citation>
    <PMID>14501439</PMID>
  </reference>
  <reference>
    <citation>Bonini S, Barney NP, Schiavone M, Centofanti M, Berruto A, Bonini S, Allansmith MR. Effectiveness of nedocromil sodium 2% eyedrops on clinical symptoms and tear fluid cytology of patients with vernal conjunctivitis. Eye (Lond). 1992;6 ( Pt 6):648-52.</citation>
    <PMID>1337745</PMID>
  </reference>
  <reference>
    <citation>Bonini S, Micera A, Iovieno A, Lambiase A, Bonini S. Expression of Toll-like receptors in healthy and allergic conjunctiva. Ophthalmology. 2005 Sep;112(9):1528; discussion 1548-9.</citation>
    <PMID>16023216</PMID>
  </reference>
  <reference>
    <citation>Mendicute J, Aranzasti C, Eder F, Ostolaza JI, Salaberria M. Topical cyclosporin A 2% in the treatment of vernal keratoconjunctivitis. Eye (Lond). 1997;11 ( Pt 1):75-8.</citation>
    <PMID>9246280</PMID>
  </reference>
  <reference>
    <citation>Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol. 1990 Dec 15;110(6):641-5.</citation>
    <PMID>2248328</PMID>
  </reference>
  <reference>
    <citation>Gupta V, Sahu PK. Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye (Lond). 2001 Feb;15(Pt 1):39-41.</citation>
    <PMID>11318292</PMID>
  </reference>
  <reference>
    <citation>BenEzra D, Pe'er J, Brodsky M, Cohen E. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol. 1986 Mar 15;101(3):278-82.</citation>
    <PMID>3953723</PMID>
  </reference>
  <reference>
    <citation>Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res. 2002 May;21(3):319-39. Review.</citation>
    <PMID>12052387</PMID>
  </reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2007</study_first_posted>
  <last_update_submitted>January 27, 2009</last_update_submitted>
  <last_update_submitted_qc>January 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alessandro Lambiase</name_title>
    <organization>University of Rome Campus Bio-Medico</organization>
  </responsible_party>
  <keyword>Vernal keratoconjunctivitis</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Children</keyword>
  <keyword>Clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ketotifen</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

